Wells Fargo initiated coverage of Praxis Precision (PRAX) with an Equal Weight rating and $282 price target The firm believes sentiment towards ulixacaltamide is bullish. However, Wells finds the approval “hard to call” and ascribes a 50% probability of success. The Praxis share setup into the FFDA review is “downside biased,” the analyst tells investors in a research note.
Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PRAX:
- Praxis Precision price target raised to $1,245 from $340 at H.C. Wainwright
- Praxis Precision price target raised to $554 from $353 at TD Cowen
- Praxis Precision price target raised to $1,200 from $450 at Piper Sandler
- Praxis Precision management to meet with Jefferies
- Praxis Precision Medicines: Clarified NDA Timelines and Catalyst‑Rich 2026 Underpin Reiterated Buy Rating